Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.

Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH

Diabetes, obesity & metabolism7 Oct 2018Cited by 107 (Europe PMC)

PMID30187620DOI10.1111/dom.13522PepBankPUB-30187620

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with schizophrenia taking antipsychotics, GLP-1 receptor agonists (liraglutide in one of three pooled studies) gave 3.71 kg greater body weight loss than control after 16.2 weeks of treatment on average.
In plain wordsIn people taking antipsychotics, GLP-1 drugs led to more weight loss than control. Liraglutide was one of the drugs pooled.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss versus control
Study
n = 164
Comparator
Control
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight loss difference
3.71 kg
GLP-1RA vs control
Source sentences
Summary
After 16.2 ± 4.0 weeks of treatment, body weight loss was 3.71 kg (95% CI = 2.44-4.99 kg) greater for GLP-1RA versus control (p < 0.001), number-needed-to-treat ≥5% body weight loss = 3.8 (95% CI = 2.6-7.2).
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762001
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with schizophrenia taking antipsychotics, waist circumference was significantly lower with GLP-1 receptor agonists than with control.
In plain wordsIn people taking antipsychotics, GLP-1 drugs lowered waist size more than control did.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 164
Comparator
Control
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Waist circumference, body mass index, HbA1c, fasting glucose and visceral adiposity were each significantly lower with GLP-1RA.
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762003
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with schizophrenia taking antipsychotics, body mass index was significantly lower with GLP-1 receptor agonists than with control.
In plain wordsIn people taking antipsychotics, GLP-1 drugs lowered body mass index more than control did.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n = 164
Comparator
Control
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Waist circumference, body mass index, HbA1c, fasting glucose and visceral adiposity were each significantly lower with GLP-1RA.
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762004
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with schizophrenia taking antipsychotics, HbA1c was significantly lower with GLP-1 receptor agonists than with control.
In plain wordsIn people taking antipsychotics, GLP-1 drugs lowered HbA1c more than control did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 164
Comparator
Control
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Waist circumference, body mass index, HbA1c, fasting glucose and visceral adiposity were each significantly lower with GLP-1RA.
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762005
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with schizophrenia taking antipsychotics, fasting glucose was significantly lower with GLP-1 receptor agonists than with control.
In plain wordsIn people taking antipsychotics, GLP-1 drugs lowered fasting blood sugar more than control did.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose
Study
n = 164
Comparator
Control
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Waist circumference, body mass index, HbA1c, fasting glucose and visceral adiposity were each significantly lower with GLP-1RA.
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762006
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with schizophrenia taking antipsychotics, visceral adiposity was significantly lower with GLP-1 receptor agonists than with control.
In plain wordsIn people taking antipsychotics, GLP-1 drugs lowered belly fat more than control did.
Peptide
Liraglutide
Outcome
DecreaseVisceral adiposity
Study
n = 164
Comparator
Control
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Waist circumference, body mass index, HbA1c, fasting glucose and visceral adiposity were each significantly lower with GLP-1RA.
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762007
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with schizophrenia taking antipsychotics, the number needed to treat with a GLP-1 receptor agonist for at least 5% body weight loss was 3.8.
In plain wordsIn people taking antipsychotics, about 4 people needed a GLP-1 drug for one to lose at least 5% of body weight.
Peptide
Liraglutide
Outcome
Not applicableNumber needed to treat for 5% or more body weight loss
Study
n = 164
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
Number needed to treat
3.8 patients
>=5% body weight loss
Source sentences
Summary
number-needed-to-treat ≥5% body weight loss = 3.8 (95% CI = 2.6-7.2).
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762002
08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with schizophrenia taking antipsychotics, nausea was more common with GLP-1 receptor agonists than with control (53.6% versus 27.5%).
In plain wordsIn people taking antipsychotics, nausea was more common with GLP-1 drugs than with control.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n = 164
Comparator
Control
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Nausea frequency
53.6%
GLP-1RA
Nausea frequency
27.5%
control
Source sentences
Summary
Nausea was more common with GLP-1RAs than control (53.6% vs. 27.5%, p = 0.002, number-needed-to-harm = 3.8).
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762009
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients treated with clozapine or olanzapine, GLP-1 receptor agonists gave greater body weight loss (4.70 kg) than in patients on other antipsychotics (1.5 kg).
In plain wordsIn people taking clozapine or olanzapine, GLP-1 drugs led to more weight loss than in people taking other antipsychotics.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss in clozapine/olanzapine-treated patients
Study
n: not reported in source
Comparator
Patients on other antipsychotics
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight loss
4.7 kg
clozapine/olanzapine
Body weight loss
1.5 kg
other antipsychotics
Source sentences
Summary
Body weight loss with GLP-1RAs was greater for clozapine/olanzapine-treated patients (n = 141) than other antipsychotics (n = 27) (4.70 kg, 95% CI = 3.13-6.27 vs. 1.5 kg, 95% CI = -1.47-4.47) (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3018762008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.